Novel treatments for anxiety and depression: hurdles in bringing them to the market

被引：24

作者：

Buller, R ^{[1
]}

Legrand, V ^{[1
]}

机构：

[1] Quintiles France, F-92564 Paris, France

来源：

DRUG DISCOVERY TODAY | 2001年 / 6卷 / 23期

关键词：

D O I：

10.1016/S1359-6446(01)02043-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Anxiety and depressive disorders are the most common psychiatric conditions. The medical need for newer, better-tolerated and more efficacious treatments remains high. However, drug development is time-consuming and has a high rate of failed or inconclusive trials. Improvements in study design, investigator training and early proof-of-concept studies are being discussed as means to decrease failure rates and the duration of development. So far, no uniformly applicable 'magic formulas' for success have been discovered. The most promising approach to overcome these hurdles appears to be a sound study design carried out by experienced professionals in the clinic and in industry.

引用

收藏

页码：1220 / 1230

页数：11

相关论文

共 64 条

[51] Neurokinin1 receptor antagonists as potential antidepressants [J].

Stout, SC ;

Owens, MJ ;

Nemeroff, CB .

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :877-906

[52] Placebo-controlled trials and active-control trials in the evaluation of new treatments - Part 1: Ethical and scientific issues [J].

Temple, R ;

Ellenberg, SS .

ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :455-463

[53]

Thase ME, 1999, J CLIN PSYCHIAT, V60, P23

[54]

THASE ME, 1992, J CLIN PSYCHIAT, V53, P32

[55]

Thompson C, 1999, J CLIN PSYCHIAT, V60, P18

[56]

Uhlenhuth E H, 1999, Depress Anxiety, V9, P107, DOI 10.1002/(SICI)1520-6394(1999)9:3<107::AID-DA2>3.0.CO

[57]

2-T

[58] International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders [J].

Uhlenhuth, EH ;

Balter, MB ;

Ban, TA ;

Yang, K .

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (06) :23S-29S

[59] International study of expert judgement on therapeutic use of benzodiazepines and other psychotherapeutic medications .2. Pharmacotherapy of anxiety disorders [J].

Uhlenhuth, EH ;

Balter, MB ;

Ban, TA ;

Yang, K .

JOURNAL OF AFFECTIVE DISORDERS, 1995, 35 (04) :153-162

[60] NKP608: a selective NK-1 receptor antagonist with anxiolytic-like effects in the social interaction and social exploration test in rats [J].

Vassout, A ;

Veenstra, S ;

Hauser, K ;

Ofner, S ;

Brugger, F ;

Schilling, W ;

Gentsch, C .

REGULATORY PEPTIDES, 2000, 96 (1-2) :7-16

← 1 2 3 4 5 6 7 →